The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...

Last year, GSK also added to its respiratory pipe with an agreement to buy Bellus Health for around $2 billion, adding a P2X3 antagonist, camlipixant, in late-stage development as a chronic cough ...

Roche’s decision eliminates a cough candidate that was differentiated from Merck & Co.’s once-rejected gefapixant and GSK’s phase 3 camlipixant ... UCB broke the news of the fifth removal ...

especially when considering the acquisition of Bellus Health by GSK last year for $2 billion. Bellus's product, camlipixant, also aimed at treating refractory chronic cough, was in Phase 3 with ...

The firm's valuation of Trevi Therapeutics at an enterprise value of $269 million is seen as potentially undervalued, especially when considering the acquisition of Bellus Health by GSK last year for ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GSK: Related Stocks Indices ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

The firm's stance will likely be reassessed as GSK provides updates on its pipeline development and potential market catalysts. In other recent news, GlaxoSmithKline PLC (GSK) has reported a ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...